Category - Executive Moves

Executive Moves

Three key appointments strengthen Amphista’s clinical development capabilities

Closely held Amphista Therapeutics has announced the appointments of Dr. Lisa Butler as SVP of clinical operations, Dr. Alexandra Sevko as VP of translational science, and Nicola Lindsay as head of project and portfolio...

October 23, 2025

Executive Moves

Dr. Bali Pulendran joins Candel’s research advisory board

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of internationally recognized expert in systems immunology and vaccinology, Bali Pulendran, PhD, to Candel’s research advisory board. Dr. Pulendran is the...

October 16, 2025

Executive Moves

James Rawls, PharmD, joins LB as SVP of regulatory affairs

LB Pharmaceuticals (NASDAQ: LBRX) has announced the appointment of James Rawls, PharmD, as senior vice president (SVP) of regulatory affairs. With more than 25 years of regulatory leadership experience across global...

October 14, 2025

Executive Moves

Cantargia appoints Dr. Wolfram Dempke as CMO

Cantargia (Nasdaq Stockholm: CANTA) has announced the appointment of Wolfram Dempke, MD, PhD, MBA as chief medical officer (CMO), effective immediately. Dr. Morten Lind Jensen, who has served as CMO since March 2025...

October 2, 2025

Executive Moves

Dr. Tiffany Inglis joins Sera as CMO

Sera Prognostics (NASDAQ: SERA) has announced the appointment of Tiffany Inglis, MD, FACOG, as chief medical officer (CMO). Dr. Inglis brings extensive clinical leadership expertise to Sera. As CMO, she will lead...

October 1, 2025

Executive Moves

Dr. Usman Azam appointed president and CEO of Cue

Cue Biopharma (NASDAQ: CUE) has announced that Usman Azam, MD has been appointed president and CEO of Cue Biopharma, effective today. Daniel Passeri will transition from his current role as CEO to one of strategic...

September 30, 2025

Executive Moves

Onco appoints Dr. Michael Lock to scientific and clinical advisory board

Onco-Innovations (CBOE CA: ONCO; Frankfurt: W1H, WKN: A3EKSZ; OTCQB: ONNVF) has announced the appointment of staff radiation oncologist, Dr. Michael Lock, to its scientific and clinical advisory board. Dr. Lock is a...

September 23, 2025

Executive Moves

Lucid appoints policy leader Danielle Scelfo as SVP, Market Access & Gov’t Affairs

Lucid Diagnostics (NASDAQ: LUCD) announced the appointment of Danielle Scelfo as SVP, Market Access & Government Affairs, reporting to the CEO. With more than 25 years of strategic and operational experience across...

September 16, 2025

Executive Moves

ALX appoints Dr. Barbara Klencke as interim CMO

ALX Oncology Holdings (NASDAQ: ALXO) has announced the appointment of board member Barbara Klencke, MD, as interim chief medical officer, (CMO). According to ALX, Dr. Alan Sandler is departing from the role of CMO and...

September 12, 2025

Executive Moves

MedX appoints Dr. Paul Matts as strategic advisor

MedX Health (TSXV: MDX) has announced the appointment of Dr. Paul J. Matts, internationally recognized skin scientist, biochemist, and educator, as strategic advisor. Dr. Matts is an academic and industry leader, as...

September 9, 2025

Category - Executive Moves

Subscribe